Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS. Braciak TA, et al. Among authors: spiekermann k. Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018. Oncoimmunology. 2018. PMID: 30228941 Free PMC article.
[Hematology 2010].
Dreyling M, Subklewe M, Braess J, Spiekermann K. Dreyling M, et al. Among authors: spiekermann k. Dtsch Med Wochenschr. 2010 Jun;135(25-26):1322-5. doi: 10.1055/s-0030-1255163. Epub 2010 Jun 16. Dtsch Med Wochenschr. 2010. PMID: 20556691 Review. German. No abstract available.
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK. Greif PA, et al. Among authors: spiekermann k. Blood. 2012 Jul 12;120(2):395-403. doi: 10.1182/blood-2012-01-403220. Epub 2012 May 30. Blood. 2012. PMID: 22649106 Free article. Clinical Trial.
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Opatz S, Polzer H, Herold T, Konstandin NP, Ksienzyk B, Zellmeier E, Vosberg S, Graf A, Krebs S, Blum H, Hopfner KP, Kakadia PM, Schneider S, Dufour A, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK, Greif PA. Opatz S, et al. Among authors: spiekermann k. Blood. 2013 Sep 5;122(10):1761-9. doi: 10.1182/blood-2013-01-476473. Epub 2013 Jul 22. Blood. 2013. PMID: 23878140 Free article. Clinical Trial.
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M. Krupka C, et al. Among authors: spiekermann k. Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3. Blood. 2014. PMID: 24300852 Free article.
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H. Janke H, et al. Among authors: spiekermann k. PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560. eCollection 2014. PLoS One. 2014. PMID: 24608088 Free PMC article.
Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.
Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A. Witter K, et al. Among authors: spiekermann k. Bone Marrow Res. 2014;2014:541345. doi: 10.1155/2014/541345. Epub 2014 Apr 3. Bone Marrow Res. 2014. PMID: 24860670 Free PMC article.
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K. Sandhöfer N, et al. Among authors: spiekermann k. Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. Epub 2014 Oct 17. Leukemia. 2015. PMID: 25322685
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I. Vick B, et al. Among authors: spiekermann k. PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925. eCollection 2015. PLoS One. 2015. PMID: 25793878 Free PMC article.
233 results